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Note
Bad Blood: An Examination of the Constitutional
Deficiencies of the FDA’s “Gay Blood Ban”
Mathew L. Morrison*
When twenty-six-year-old Evan Low was sworn in as the
mayor of Campbell, California, he made headlines as the
1
youngest Asian-American, openly gay mayor in the nation. As
a result of his dedication to civic engagement, government
transparency, and fiscal responsibility, Mayor Low enjoyed
2
popularity and respect as a public servant. Mayor Low did not,
however, receive similar treatment under the law as a gay
man. Though Mayor Low now has access to rights that, until
recently, were unavailable to him and other LGBT Americans,
such as marriage and federal tax benefits, he is still barred
from donating blood pursuant to federal policy which bans gay
3
men from donating blood. Despite coordinating a blood drive
 J.D. Candidate 2015, University of Minnesota Law School; B.A. 2012,
Northwestern State University of Louisiana. Thank you to the professors who
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and Professor Dale Carpenter. Thank you also to the incredible mentors who
have supported me through the years, including Dr. Holly Stave, Charlie
Penrod, and Dr. Davina McClain. Many thanks to the staff and editors of
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1. Chris Vongsarath, Campbell’s Evan Low Sworn in As Youngest AsianAmerican, Openly Gay Mayor in the Country, SAN JOSE MERCURY NEWS (Dec.
2, 2009), http://www.mercurynews.com/breaking-news/ci_13909520.
2. Id.
3. Tracy Miller, California Mayor Calls for End to FDA Ban on Gay Male
Blood Donations, DAILY NEWS (Aug. 21, 2013), http://www.nydailynews
.com/life-style/health/calif-mayor-calls-gay-blood-donor-ban-article-1.1433054.
The recent Supreme Court decision in United States v. Windsor furthered
what many call the “gay rights” movement by striking down a key portion of
the Defense of Marriage Act (DOMA), which discriminated against homosexuals as a class. Defense of Marriage Act, Pub. L. No. 104-199, § 3, 110 Stat.
2419, 2419 (1996), invalidated by United States v. Windsor, 133 S. Ct. 2675,
2695–96 (2013). Many states have also legalized gay marriage. Ryan L.
Sievers, Same-Sex Marriage Is Legal in 16 States, and This Is Good,
CHICAGONOW (Nov. 16, 2013, 12:41 AM), http://www.chicagonow.com/art-of
-business/2013/
11/same-sex-marriage-is-good.
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with the American Red Cross, Mayor Low was not allowed to
4
donate blood at the event. The ban, enacted in 1983, prohibits
all men who have had sex with other men (MSM) since 1977
from donating blood, and is regarded by many as being unnec5
essarily discriminatory.
Mayor Low is only the latest in an ever-increasing line of
individuals who have been banned from donating blood since
6
the guideline was implemented in 1983. The Food and Drug
Administration (FDA) currently prohibits MSM from donating
blood due to concerns that, as a population, MSM are at a higher risk for carrying HIV, hepatitis B, and other diseases that
7
are transmittable via blood transfusions. The FDA’s concern of
assuring the safety of patients receiving blood was the primary
8
impetus for the ban. The guideline was thus first implemented
at the outset of the HIV/AIDS epidemic, when the disease was
9
most rampant in the MSM community. Even as late as 2010,
the MSM population accounted for 61% of new HIV infections,
and 77% of male HIV infections were attributed to male-to10
male sexual contact.
Though the FDA currently cites statistics to justify its policies, many argue that the guidelines are now outdated and no
11
longer based on “sound science.” Others contend that the ban
is discriminatory and, as such, unconstitutional under U.S.
12
law. The FDA disagrees with both arguments and to this day
13
maintains its “gay blood ban.” Recent developments may see a
4. Miller, supra note 3.
5. See id.
6. See id.
7. Blood Donations from Men Who Have Sex with Other Men Questions
and Answers, FDA, http://www.fda.gov/BiologicsBloodVaccines/BloodBlood
Products/QuestionsaboutBlood/ucm108186.htm (last updated Mar. 8, 2015)
[hereinafter FDA Guidelines]. For the sake of consistency, this Note will refer
to the FDA’s policy as the “gay blood ban” throughout. Note that the FDA has
recently indicated its willingness to alter the policy. See infra Part I.B. However, as this Note will discuss, this does not ameliorate the substantive problems of the current policy.
8. See FDA Guidelines, supra note 7.
9. See id.
10. Id.
11. Gillian Mohney, FDA Ban on Gay Men as Blood Donors Opposed by
American Medical Association, ABC NEWS (June 20, 2013), http://abcnews
.go.com/Health/american-medical-association-opposes-fda-ban-gay-men/story?
id=19436366 (quoting American Medical Association board member Dr. William Kobler).
12. See Miller, supra note 3.
13. See FDA Guidelines, supra note 7 (contending that the guideline “is
not based on any judgment concerning the donor’s sexual orientation,” and
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modified ban implemented in the near future, but as this Note
will discuss, those changes are insufficient. Despite the FDA’s
attempts at justifying the ban, the fact remains that heterosexual individuals who engage in risky sexual behavior, gay women, and other populations with potential exposure to HIV and
14
other diseases face no such ban.
The gay blood ban raises several questions of law. This
Note examines those issues and offers a solution that attempts
to bridge the gap between the government’s need to ensure the
safety of the blood supply while also respecting the dignity of
an oft-maligned population. Part I discusses the background
and rationale for the original implementation of the gay blood
ban, as well as recent developments in science, society, and law
that affect the issue. Part II briefly analyzes legal and normative questions raised by the ban before delving into the most
viable challenge to the ban, based on constitutional principles
of equality. Part III offers a new framework by which the FDA
can effectively and in a nondiscriminatory manner regulate the
nation’s blood supply.
I. DEVELOPMENT OF THE HIV EPIDEMIC AND
SUBSEQUENT REGULATION
Though HIV and AIDS are understood in the scientific
15
community today, this was not always the case. This Part examines both the history of the HIV/AIDS epidemic and the subsequent regulatory framework that arose as an attempt to protect the nation’s blood supply. Section A briefly recounts the
history of the HIV/AIDS epidemic in the context of its association as a “gay” disease as well as the developments in science
and medicine that have led to current general knowledge of the
virus. Section B discusses the history of the FDA’s regulatory
approach to the HIV virus in the context of blood donations.
A. HISTORY OF THE HIV/AIDS EPIDEMIC
The association between gay men and HIV, and the fears
consequently produced by the connection, were justified at one
point. The beginning years of the epidemic in the United States
were filled with confusion and uncertainty. Cases were reportthat currently cited statistics are sufficient evidence for continuing the ban).
14. Id.
15. AIDS is the syndrome of medical complications arising from an HIV
infection. See generally What Is HIV/AIDS?, AIDS.GOV, http://www.aids.gov/
hiv-aids-basics/hiv-aids-101/what-is-hiv-aids (last updated Apr. 29, 2014) (explaining the relationship between HIV and AIDS).
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ed as early as October of 1980, when an individual dubbed “Patient Zero” infected men at a New York City bath house with
16
the virus that would eventually come to be known as HIV. The
new disease was first acknowledged by the Centers for Disease
Control (CDC) when it published reports of a rare lung infection, Pneumocystis carinii pneumonia (PCP), affecting several
17
otherwise healthy young gay men in Los Angeles. Within days
of the publication, doctors across the United States inundated
18
the CDC with reports of similar infections in young gay men.
Subsequent reports of diseases in the gay community were not
confined to PCP. Other diseases that were reported included
Kaposi’s Sarcoma, an unusually aggressive cancer that until
19
then was a rare occurrence. The infections were exclusive to
20
gay men at this point.
The still-unknown disease affecting men mostly in New
York and California became so associated with homosexuals
that it was initially called the “Gay-related immune disease,”
and this name gained some popularity until the occurrence of
21
infections in heterosexual Haitians. Though other popula22
tions, such as hemophiliacs, soon joined homosexuals and
Haitians as groups associated with the disease, in the public’s
23
eye the disease was largely a homosexual problem. It was not
until July of 1982 that the disease was officially renamed as
24
“acquired immunodeficiency syndrome,” or AIDS.
When it became clear in 1982 that a new disease was rapidly spreading throughout the United States, several clinics
and medical service organizations cropped up throughout the
25
country, many emphasizing health services for gay men. At
16. AIDS in New York: A Biography, N.Y. MAG., http://nymag.com/
news/features/17158 (last visited Apr. 20, 2015).
17. A Timeline of AIDS, AIDS.GOV, http://aids.gov/hiv-aids-basics/hiv
-aids-101/aids-timeline (last visited Apr. 20, 2015).
18. Id.
19. Id.
20. Id.
21. AIDS in New York, supra note 16.
22. Hemophilia is a blood disorder that prevents blood from clotting
properly in wounds. As a result, hemophiliacs bleed for longer periods of time,
which is not a problem for cuts but can become life-threatening with larger
injuries. Hemophilia, MAYO CLINIC (Sept. 26, 2014), http://www.mayoclinic
.org/diseases-conditions/hemophilia/basics/definition/con-20029824.
23. AIDS in New York, supra note 16.
24. Id.
25. A Timeline of AIDS, supra note 17. A few examples include New York
City’s Gay Men’s Health Crisis, the nation’s first community-based HIV/AIDS
service provider, the San Francisco AIDS Foundation, and the first American

2015]

BAD BLOOD

2367

this time, little was known about the disease, and Congress
passed reactive legislation to fund surveillance and AIDS research through the CDC and the National Institutes of
26
Health. In April of 1982, the first CDC estimate of the population affected by the disease numbered in the tens of thou27
sands. In late 1982, an AIDS infected donor transmitted the
disease to an infant through a blood transfusion, causing the
28
nation’s first panic over the blood supply.
The final straw concerning blood donations was conclusive
research indicating that AIDS was transmitted through sexual
29
contact and, potentially, blood transfusions. One 1983 Morbidity and Mortality Weekly Report indicated that the occurrence
of AIDS cases paralleled that of another sexually transmitted
disease, hepatitis B, and that “[t]he likelihood of blood transmission is supported by the occurrence of AIDS among IV drug
30
abusers.” At this time, there was no way to detect AIDS in
asymptomatic patients, and the precise cause was still un31
known. Though the Report outlined some ways by which to
reduce risk of infection, it conceded that, until AIDS was better
understood by the medical community, the organization’s ability to detect and prevent the disease was “somewhat compro32
mised.”
With widespread awareness of AIDS came concern over the
nation’s blood supply. Already fueled by cases of infection
through blood transmission, the CDC initially recommended
that all at-risk populations, such as intravenous drug users and
33
MSM, refrain from donating blood or plasma. According to the
FDA, 1983 marked the first time that the MSM population was

AIDS clinic, established in San Francisco. Id.
26. Id.
27. Id.
28. AIDS in New York, supra note 16.
29. CDC, Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS), 32 MORBIDITY & MORTALITY WKLY. REP. 101 (Mar. 4, 1983),
available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00001257.htm.
30. Id.
31. Id.
32. Id.
33. Id. Though blood donation guidelines had not yet been affected by concern for the blood supply, signs were already indicating that the FDA was preparing a guidelines overhaul. Id. (“The Food and Drug Administration (FDA)
is preparing new recommendations for manufacturers of plasma derivatives
and for establishments collecting plasma or blood. This is an interim measure
to protect recipients of blood products and blood until specific laboratory tests
are available.”).
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34

singled out and discouraged from donating, though the ban
35
would not become codified in FDA regulations until 1992.
Though undeveloped guidelines were implemented in 1983, the
response of the FDA and the blood banking industry was highly
criticized as “woefully inept” and ineffective at initially protect36
ing the blood supply. Given that the precise viral origin of
AIDS was still unknown, there was no way to screen for infect37
ed blood, and so deferral of the MSM population eventually
38
gained traction as the next best viable option.
The “blood ban” did not originally apply to all individuals
in the MSM population. Initially, the Public Health Service only identified homosexual and bisexual men who had multiple
sex partners as one of the high-risk groups, and accordingly
39
recommended that they defer from donating. Though some
groups argued that the recommendation went too far in discriminating against the gay male population, others criticized
40
the ban for not going far enough. Eventually, the FDA issued
guidelines meant to serve as a temporary fix, and the gay
41
community reluctantly acquiesced to the policy. In 1992, however, the ban became permanent, and the FDA instituted a lifetime blood donation ban on the MSM population without regard to other factors, such as number of sex partners or history
42
of drug use. Given the ominous danger of infection through
43
blood transfusions, the subsequent public health concerns,
34. See Shawn Carroll Casey, Illicit Regulation: A Framework for Challenging the Procedural Validity of the “Gay Blood Ban,” 66 FOOD & DRUG L.J.
551, 551 (2011) (noting that, at first, the CDC only “recommended” that high
risk groups, including MSM, be asked to defer from donating).
35. FDA Guidelines, supra note 7. As a federal agency, the FDA has the
power to make rules. 5 U.S.C. § 553 (2012). Several laws give the FDA the authority to specifically regulate the nation’s blood supply. Food, Drug, and
Cosmetics Act, 21 U.S.C. § 301 (2012); Public Health Service Act, 42 U.S.C.
§ 201 (2012); Biologies Act, 42 U.S.C. § 262 (2012).
36. See Linda M. Dorney, Culpable Conduct with Impunity: The Blood Industry and the FDA’s Responsibility for the Spread of AIDS Through Blood
Products, 3 J. PHARMACY & L. 129, 130 (1994).
37. For the purposes of this Note, the “gay blood ban” refers to the FDA’s
current policy, supra note 7, and a “deferral” refers to any period of time an
MSM must abstain from having sexual relations in order to donate blood (for
example, a one year period).
38. See Casey, supra note 34, at 554.
39. CDC, supra note 29.
40. Casey, supra note 34, at 554–56.
41. See id. at 555.
42. See FDA Guidelines, supra note 7.
43. See Francine A. Hochberg, HIV/AIDS and Blood Donation Policies: A
Comparative Study of Public Health Policies and Individual Rights Norms, 12
DUKE J. COMP. & INT’L L. 231, 235 (2002) (“[T]he success of HIV transmission
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and general ignorance of how the disease worked, as well as
how to screen it, the ban, at the time it was implemented, was
44
the best way to prevent the spread of AIDS.
B. A NEW REGULATORY REGIME: RESPONSES TO THE HIV/AIDS
EPIDEMIC
As science and technology change, so do societal views. In
some instances, the legal landscape reflects these alterations.
Fifteen years ago, the concept of same-sex marriage was a novel idea and far from reality; today thirty-seven states and the
45
District of Columbia have legalized same-sex marriage. Similarly, the evolving landscape of medical knowledge, or the lack
thereof, greatly impacted HIV/AIDS regulation across the
46
board and continues to do so. This Section recounts the history of the regulatory framework arising out of the HIV/AIDS epidemic. It also discusses the FDA’s recent statements regarding
a potential policy change—one that still raises the problems of
the lifetime ban.
As AIDS became more widespread throughout the country,
so did the impetus to understand the disease. It was no longer
a mysterious illness affecting a small population, rather, “the
47
greatest tragedy of the twentieth century.” With the drive to
understand the new killer disease came a wealth of scientific
information and, eventually, the development of technologies
that led to a better understanding of how AIDS worked and
48
how to prevent its transmission.
is over 90% when infected blood is transfused to a formerly uninfected person.”) (citing BARRY D. SCHOUB, AIDS AND HIV IN PERSPECTIVE: A GUIDE TO
UNDERSTANDING THE VIRUS AND ITS CONSEQUENCES 111, 114 (2d ed. 1999)).
44. See Mike Darling, Banned for Life, MEN’S HEALTH (2013), http://
www.menshealth.com/banned-for-life (noting that there was no viable way of
testing blood or plasma for HIV at the time the bans were implemented).
45. See Same-Sex Marriage Laws, NAT’L CONF. ST. LEGISLATURES (Feb.
19, 2015), http://www.ncsl.org/research/human-services/same-sex-marriage
-laws.aspx. The issue of same-sex marriage continues to be in the spotlight, as
the Sixth Circuit recently upheld bans against same-sex marriage, creating
the first circuit split on the issue. Id.
46. For instance, current laws criminalizing knowing infection of sexual
partners with HIV has in recent years been criticized as the landscape has
shifted. See generally Kim Shayo Buchanan, When Is HIV a Crime? Sexuality,
Gender and Consent, 99 MINN. L. REV. 1231 (2015) (arguing that decriminalization would best address the “discriminatory social meaning and effects of
HIV criminalization”).
47. Muser Entertainment, Madonna - In This Life (The Girlie Show),
YOUTUBE (Mar. 7, 2009), http://www.youtube.com/watch?v=7sBOxrsCmPo
(dedicating a song to her friends who died from AIDS).
48. See generally Mohney, supra note 11 (discussing the request of the
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In 1985, shortly after acceptance of the MSM donor ban became mainstream, HIV was officially identified as the retrovi49
rus responsible for AIDS. Following this discovery, the FDA
licensed a test for the purpose of detecting HIV’s presence in
donated blood and blood products, known as the enzyme50
linked-immuno-sorbent-assay, or ELISA. Though this test was
a breakthrough, estimates indicated that adding the test to the
51
blood collection process would be expensive. In the midst of
this developing technology and increasing ability to test accurately for HIV/AIDS, the FDA tightened its donation policy in
52
1992. The resulting policy banned all men who had engaged in
sexual activities with other men since 1977 from donating
53
blood. Though the ELISA test was the beginning, it certainly
54
was not the most effective method of HIV detection. As recently as 2012, a testing method known as Nucleic Acid Testing
(NAT) has been offered as a more effective method of HIV de55
56
tection. It is more accurate and yields quicker results. Instead of testing for HIV antibodies, NAT uses primers that
identify RNA or DNA in blood samples as HIV-1 RNA, and is
57
used for detecting other diseases as well. Studies indicate that
58
NAT testing has increased HIV detection yield by 23%.
With an ever-increasing body of knowledge and technology
better equipped to test for the virus in blood samples, the gay

U.S. Department of Health and Human Services for “information from additional studies on the potential outcomes of changing the blood donation criteria”).
49. Casey, supra note 34, at 556.
50. See Doe v. Am. Nat’l Red Cross, 866 F. Supp. 242, 244–45 (D. Md.
1994).
51. See id. at 245.
52. Casey, supra note 34, at 556.
53. Id.
54. See generally FDA, GUIDANCE FOR INDUSTRY USE OF NUCLEIC ACID
TESTS ON POOLED AND INDIVIDUAL SAMPLES FROM DONORS OF WHOLE BLOOD
AND BLOOD COMPONENTS, INCLUDING SOURCE PLASMA, TO REDUCE THE RISK
OF TRANSMISSION OF HEPATITIS B VIRUS (2012), available at http://www.
fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatory
Information/Guidances/Blood/UCM327895.pdf.
55. Id. Various iterations of the test were first licensed by the FDA for use
beginning in 2006 or so, but the FDA began to encourage their use much later.
Id.
56. See Debra Kain, Adding Nucleic Acid Testing to HIV Screening May
Help Identify More People with HIV, UC SAN DIEGO NEWS CENTER (June 15,
2010), http://ucsdnews.ucsd.edu/archive/newsrel/health/06-15TestingHIV.asp.
57. FDA, supra note 54, at 2.
58. Kain, supra note 56.
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blood ban is losing popularity in the medical community and
60
general population. Other countries, which previously had followed the United States’ lead in instituting lifetime bans, have
61
now lifted those bans partially or entirely. As early as 1992,
the Department of Health and Human Services indicated that
HIV infections represented only a “minimal” risk to the blood
62
supply. The Health and Human Service’s Advisory Committee
on Blood Safety and Availability (ACBSA) recently found that
the current donation policies, while effective at excluding some
high risk donors, also potentially excludes low risk donations,
and as such has recommended a reevaluation of the current
63
guideline. The FDA ardently opposes updating its current policy, however, stating that it would “change this policy only if
supported by scientific data showing that a change in policy
would not present a significant and preventable risk to blood
64
recipients.” The FDA maintains that there is no threat to the
blood supply, that the MSM population remains the most high-

59. See Mohney, supra note 11 (noting that the American Medical Association now opposes the ban, arguing that “‘[t]he lifetime ban on blood donation
for men who have sex with men is discriminatory and not based on sound science’” (quoting AMA board member Dr. William Kobler)).
60. See Darling, supra note 44; Tyler Smith, Gay Blood Considered Risk
for Donation, FOURTH EST. (Sept. 6, 2013), http://www.fourthestatenewspaper
.com/opinion/2013/09/06/gay-blood-considered-risk-for-donation.
61. See generally Clive R. Seed et al., No Evidence of a Significantly Increased Risk of Transfusion-Transmitted Human Immunodeficiency Virus in
Australia Subsequent to Implementing a 12-Month Deferral for Men Who Have
Had Sex with Men, 50 TRANSFUSION 2722 (2010); Philip Caulfield, Britain To
Allow Gay Men To Donate Blood, DAILY NEWS (Apr. 10, 2011, 11:46 AM),
http://www.nydailynews.com/news/world/Britain-gay-men-donate-blood-policystep-u-s-ban-gay-donors-article-1.110214 (reporting that Britain will institute
a ten-year deferral period in place of the previous lifetime ban); Scott Roberts,
Mexico Lifts Ban on Gay Men Donating Blood, PINK NEWS (Dec. 27, 2012, 6:29
PM),
http://www.pinknews.co.uk/2012/12/27/mexico-lifts-ban-on-gay-men
-donating-blood (“Gay and bisexual men, who have a history of using condoms,
who do not inject drugs, and are not sex workers can now donate.”); Elizabeth
Trovall, Gays and Lesbians in Chile Now Allowed To Donate Blood, SANTIAGO
TIMES (Apr. 25, 2013), http://www.archive.today/KNJUm (reporting a lift of
Chile’s current ban with no time deferrals).
62. Memorandum from the Dir. of the Ctr. for Biologics Evaluation & Research to All Registered Blood Establishments, Revised Recommendations for
the Prevention of Human Immunodeficiency Virus (HIV) Transmission by
Blood and Blood Products (Apr. 23, 1992) (on file with the FDA), available at
http://www.fda.gov/downloads/UCM062834.pdf.
63. FDA Guidelines, supra note 7.
64. Id. There was also considerable doubt as to whether the FDA could
change this policy even if it had the desire to do so without going through the
arduous notice and comment procedure. See Paralyzed Veterans of Am. v. D.C.
Arena L.P., 117 F.3d 579, 586 (D.C. Cir. 1997); infra Part II.B.2.
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ly susceptible to HIV infection, and that testing technology is
65
not adequate to justify a lift on the ban.
Though the FDA argues that the MSM population is still
high risk to the point of justifying a ban, it has indicated a willingness to modify its policy. On December 23, 2014, the FDA
issued a statement indicating that, in light of scientific data
and the recommendations of advisory committees to the U.S.
Department of Health and Human Services (HHS), it will soon
66
consider altering the ban. Specifically, the FDA is willing to
“change . . . the blood donor deferral period for men who have
sex with men from indefinite deferral to one year since the last
67
sexual contact.” Taking note of its prior error in implementing
the lifetime ban, the FDA plans to initiate the appropriate no68
tice and comment procedure.
Substantively, this development does little, if anything, to
improve the current state of affairs for gay and bisexual men.
The notice and comment procedure does not guarantee that the
FDA will implement the new policy, only that it will consider
its implementation. Further, the FDA will not consider lifting
69
the ban in its entirety. For some, this may appear to be progress. But this is the bottom line: the best case scenario sees
the FDA implementing a one-year deferral period specifically
addressing the MSM population; the worst case scenario sees
no change in the policy if the notice and comment procedure results in enough opposition to the proposed change. Despite its

65. See infra Part II.B.2.
66. FDA Commissioner Margaret A. Hamburg’s Statement on FDA’s Blood
Donor Deferral Policy for Men Who Have Sex with Men, FDA (Dec. 23, 2014),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427843
.htm [hereinafter FDA Statement].
67. Id.
68. Id. (“The FDA intends to issue a draft guidance recommending this
proposed change in policy in 2015, which will also include an opportunity for
public comment. We encourage all stakeholders to take this opportunity to
provide any information the agency should consider, and look forward to receiving and reviewing these comments.”).
69. The FDA has already indicated an extreme reluctance in even altering
the policy. See FDA Panel Wary of Lifting Ban on Gay Blood Donors,
WTSP.COM (Dec. 3, 2014, 4:26 PM), http://www.wtsp.com/story/news/health/
2014/12/03/fda-panel-wary-of-lifting-ban-on-gay-blood-donors/19851057 (stating that the FDA’s experts did not embrace even the twelve-month deferral
period proposal). One FDA official stated, “If I look at the science I would be
very wary of a one-year deferral . . . . It sounds to me like we’re talking about
policy and civil rights rather than our primary duty, which is transfusion safety.” Id. (quoting Dr. Susan Leitman).
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willingness to consider a policy alteration, the FDA’s position
70
on HIV and the gay male population has not changed.
The FDA’s assertions regarding HIV infections in the gay
male population are not completely unfounded. Despite years of
prevention and HIV awareness efforts and improved testing
technology, the HIV infection rate in the U.S. has remained
71
stable. In addition, early detection, which is critical to controlling the epidemic, is potentially challenging due to the window
of time immediately following infection when testing accuracy
72
is low. Perhaps the most unsettling fact is that young gay men
are increasingly becoming infected with HIV, despite the fact
73
that infection rates remain stable. Of the 47,500 Americans
who were infected with HIV in 2010, 26% were adolescents or
74
young adults aged 13–24. More disheartening is the fact that,
from 2008 to 2011, young MSM (aged 13–24) accounted for the
75
greatest percentage increase in diagnosed HIV infection.
The gay community also remains the predominant popula76
tion affected by HIV/AIDS. In 2010, the MSM population accounted for 63% of new infections, whereas the heterosexual
population accounted for 25% and the intravenous drug using
77
population accounted for 11%. In 2010, the young MSM population experienced a 22% increase in the number of new HIV
infections, which again was attributed to lack of understanding
78
of the risk of HIV. Still, though the FDA and blood banks remain responsible for maintaining the integrity of the blood
79
80
supply, a substantial portion of those in the medical and le81
gal communities maintain that the lifetime ban is now based
70. Id.
71. Kain, supra note 56.
72. Id.
73. NAT’L CTR. FOR HIV/AIDS, VIRAL HEPATITIS, STD, & TB PREVENTION,
CDC, CS249858, HIV AND YOUNG MEN WHO HAVE SEX WITH MEN 1–2 (2010)
[hereinafter HIV AND YOUNG MEN], available at http://www.cdc.gov/
healthyyouth/sexualbehaviors/pdf/hiv_factsheet_ymsm.pdf (suggesting that
this is a result of complacency in the younger generations).
74. Id.
75. Id. This amounts to around 12,000 young men each year. Further,
93% of HIV infections among males aged 13–19 are attributed to male-to-male
sexual contact. Id.
76. CDC, NEW HIV INFECTIONS IN THE UNITED STATES 1 (2012).
77. Id. at 2.
78. Id.
79. See Jan M. Bennetts, AIDS: Blood Bank Liability, 27 WILLAMETTE L.
REV. 355, 372 (1991); Dorney, supra note 36.
80. See, e.g., Mohney, supra note 11.
81. See, e.g., Casey, supra note 34.
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on outdated science and old methods of determining one’s HIV
82
status, and is consequently bad law. This is relevant because
in the past, courts have indicated that laws enacted when certain facts were relevant may be challenged by a showing that
the facts no longer exist, a principle that could be applied to the
83
FDA’s ban.
The political climate, now more than ever, warrants that
the policy be closely scrutinized. The FDA’s policy on MSM donations has incited anger in the LGBT population, and has
achieved a place in the national spotlight approaching that of
84
the marriage equality discussion. Furthermore, recent court
decisions across the country have changed the legal landscape
85
for sexual orientation-based laws and legal challenges. Thus,
the time is ripe (at least, politically) for doing away with the
ban altogether.
Politics and policy aside, however, medical breakthroughs
have vastly improved the landscape of HIV/AIDS treatment,
detection, and prevention. The combination of several factors,
such as a better understanding of HIV and HIV/AIDS detection, concerns for equal protection for LGBT citizens, and the
harsh realities of the continuing HIV epidemic, produces a difficult legal and practical question. How do we protect the nation’s blood supply, curb the spread of HIV, and still maintain
the integrity and constitutional rights of the LGBT population?
The following Part attempts to address this question and its
implications.
II. ANALYSIS OF THE GAY BLOOD BAN
Though the FDA’s blanket ban on MSM blood donations
gained momentum as a viable way to keep the nation’s blood
supply “clean,” the advent of technology and understanding of
86
the disease has led to the regulation’s growing unpopularity.
And though opposing the ban is a popular political position to
82. Id. at 553 (arguing for a one-year deferral period).
83. See United States v. Carolene Prods. Co., 304 U.S. 144, 153 (1938)
(“[T]he constitutionality of a statute predicated upon the existence of a particular state of facts may be challenged by showing to the court that those facts
have ceased to exist.” (citing Chastleton Corp. v. Sinclair, 264 U.S. 543, 548–
49 (1924))).
84. See, e.g., Alissa Scheller & Anna Almendrala, Why Even a 12-Month
Ban on Blood Donations from Gay Men Makes No Sense, HUFFINGTON POST
(Dec. 23, 2014, 9:33 PM EST), http://www.huffingtonpost.com/2014/12/23/gay
-blood-ban-deferral_n_6374374.html.
85. See infra Part II.C.
86. See supra notes 59–60 and accompanying text.
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take, there is a dearth of legal scholarship that meaningfully
addresses the policy in light of modern case law pertaining to
sexual orientation. However, that is not to say that legal challenges to the ban have not been contemplated by academics and
87
practicing attorneys.
The normative arguments against the ban are much more
88
cognizant of changing attitudes and the need for a safe and
adequate national blood supply. One source recently published
a piece arguing for a complete lift of the ban, citing the “change
89
in technology” as the primary evidence for its argument.
There is merit in this proposal. With new testing, it takes
around ten days after unsafe sex to conclusively determine
whether the individual has HIV—and thus whether the blood
90
sample is viable or not. Furthermore, within that ten-day
window, the chances of a false negative are about one in two
91
million. If every man who engaged in unsafe sex with another
man were tested, it would make sense to change the ban to a
92
deferral period of ten days after having engaged in unsafe sex.
Regardless, much uncertainty has been removed from the blood
screening process. Ultimately, it may be the normative arguments that help the hypothetical court in its decision.
87. The most recent piece regarding the gay blood ban inappropriately
addresses the situation and, though well-intentioned, comes to an inadequate
and perhaps incorrect conclusion. Ryan H. Nelson, An Indirect Challenge to
the FDA’s “Gay Blood Ban,” 23 TUL. J.L. & SEXUALITY 1 (2014). Nelson offers
what he calls a “weapon in the fight against the gay blood ban: an indirect,
state-law challenge.” Id. at 3. His solution to the problem only involves indirect challenges on the state level on the basis of “places of public accommodation” discrimination, which even he admits is impractical unless undertaken
in litigation nationwide. Id. at 16. Further, his vision of a “threat of such an
unthinkable, catastrophic blood shortage” resulting from this litigation pressuring the FDA into changing its policies is somewhat disturbing. Id.
88. For example, many HIV-centric laws concern only gay men, including
HIV criminalization crimes. See, e.g., Buchanan, supra note 46, at 1240 (“[T]he
seemingly arbitrary ways in which HIV crimes diverge from their public
health rationale tend systematically to construct HIV as fairly benign when
contained within stigmatized populations such as sex workers, intravenous
drug users, and men who have sex with men. At the same time, these laws
tend to criminalize the conduct of HIV-positive people when their behavior
causes anxiety to more privileged heterosexuals, even when it poses no transmission risk.” (footnote omitted)).
89. Darling, supra note 44 (stating that inaccurate and slow testing processes are a thing of the past “thanks to a faster and far more accurate process
called Nucleic Acid Testing—NAT, for short,” and that, “[u]nlike the EIA [enzyme immunoassays] test, the NAT can detect the amount of actual virus in
the bloodstream, not just the antibodies produced to fight it”).
90. Id.
91. Id.
92. Id.
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The most popular challenge to the ban is rooted in admin93
istrative procedure. As an administrative agency, the FDA
must follow certain rules in order for its regulations and guidelines to be binding on the public. Generally, to be binding, the
agency must give notice of the proposed regulation and publish
it in the Federal Register, including specific information for the
public regarding the regulation, and may only circumvent the
process in limited circumstances, as set forth in the Adminis94
trative Procedure Act (the APA). Challengers argue that the
95
MSM policy runs afoul of these procedural requirements.
However, the key piece is missing from these arguments:
whether or not the FDA would even be able to change its policy
or an interpretation of its own rule, without going through the
96
arduous notice and comment procedure. Both questions may
be rendered moot by the FDA’s willingness to proceed with the
notice and comment process.
The FDA ban has also undergone criticism on the basis
that it violates the federal Constitution’s Equal Protection
97
Clause. There is little scholarship today that truly scrutinizes
the policy adequately in light of recent developments in sexual
orientation jurisprudence. Specifically, existing scholarship on98
ly analyzes the ban in light of Lawrence v. Texas, a critical
case that has since been superseded by subsequent case law
99
that potentially expands its holding. Given recent developments in civil rights jurisprudence, a constitutional challenge
to the FDA gay blood ban is more viable than it was in years
93. For a general discussion on the binding effects of federal agency rules
and guidelines, see generally Robert A. Anthony, Interpretive Rules, Policy
Statements, Guidances, Manuals, and the Like—Should Federal Agencies Use
Them To Bind the Public?, 41 DUKE L.J. 1311 (1992).
94. See 5 U.S.C. § 553 (2012).
95. See Casey, supra note 34, at 567.
96. There was previously a debate, to be discussed infra Part II.A, as to
whether an administrative agency must alter its initial interpretation of a
regulation by the same means of modifying the regulation itself, through the
process of notice-and-comment rulemaking. See generally Paralyzed Veterans
of Am. v. D.C. Arena L.P., 117 F.3d 579, 586 (D.C. Cir. 1997) (holding that
agencies must go through notice and comment to change their interpretations
of regulations).
97. See Michael Christian Belli, The Constitutionality of the “Men Who
Have Sex with Men” Blood Donor Exclusion Policy, 4 J.L. SOC’Y 315, 319
(2003).
98. 539 U.S. 558, 558 (2003) (holding, inter alia, that sexual conduct between two consenting adults is protected by the Fourteenth Amendment).
99. For a pre-Lawrence analysis of the ban, see generally Belli, supra note
97. See also United States v. Windsor, 133 S. Ct. 2675, 2695 (2013) (expanding
on Lawrence).

2015]

BAD BLOOD

2377

past. In fact, the constitutional challenge to the ban is now the
most important—and viable—challenge to the ban, and as
such, this Section will focus on those arguments.
This Note will primarily address the constitutional problems with the ban—either in its current state or as it would exist in the form of a one-year deferral period. However, Section A
addresses why the ban should be lifted from a normative
standpoint. Section B briefly addresses the procedural chal100
lenge to the ban and its current (lack of) viability. Section C
delves into the larger constitutional issues of the policy, taking
the analysis further than past scholarship in light of recent
court decisions. This Part seeks to demonstrate conclusively
that the legal justifications for ending the current policy should
lead to a new regulatory framework that protects the interests
of both the FDA and the MSM population.
A. THE NORMATIVE QUESTION: WHY BOTHER?
Before addressing how the ban might be challenged, it is
important to understand why the ban should be lifted. This section seeks to answer that question. Why should we challenge a
law that, from a lay perspective, inconveniences a minute portion of the population? The answer involves a balancing act the
government should strive for: protecting the national blood
supply while preserving the dignity of its citizens. Understanding why the ban should be lifted, as well as what an ideal policy
might strive to accomplish, is crucial in understanding how to
challenge it. Subsection 1 addresses the need to protect the
blood supply and Subsection 2 addresses the protection of minority interests.
1. Protecting the Integrity of Our Blood Supply
Ideally, an FDA guideline regarding blood donor requirements would adequately preserve the integrity of the nation’s
blood supply. Protecting the blood supply has two components.
First, ensuring an adequate supply must be accomplished
through sensible donation policies that allow for as large a donation pool as possible. Second, the right steps must be put in
place to ensure that the blood supply remains “clean.” This
Subsection addresses each of these concerns in turn and determines that the current guideline fails to address them.
100. However, as the Note will discuss, many of the procedural problems
with the current policy would be ameliorated if it is modified subject to a proper notice-and-comment rulemaking process.
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Doubts abound as to whether the current law is too restrictive in its attempts to keep the blood supply “clean.” As established earlier, many in the medical profession no longer consid101
er the ban to be based on sound science. Further, the FDA’s
assertion concerning the adequacy of our nation’s blood supply
102
may not be entirely accurate. Not all blood is created equal,
and while asserting that in the aggregate no shortage exists,
blood type shortages may still exist. Thus, the focus of expanding the pool of donors must address quality as well as quantity.
The rarest blood type, AB–, is represented in approximate103
ly 1.6% of our population. While considered the “universal recipient” blood type, AB– is still a valuable potential source of
104
blood donation, as are other rare types. The MSM population
contains individuals with rare blood types that are underrepre105
sented in the aggregate blood supply. Thus, though the quantitative supply may be adequate, that says nothing of rare
blood, nor does the FDA address potential MSM donors with
rare blood types that are not able to donate. Adding otherwise
viable MSM to the pool of donors has the potential to signifi106
cantly ameliorate blood shortage problems.
In addition to potentially curtailing the qualitative blood
supply, the current policy also restricts the quantitative supply.
As established before, the American Medical Association and
the Red Cross report that the current ban is unwarranted, and
101. See Mohney, supra note 11.
102. See supra text accompanying note 65.
103. See Blood Types, AM. RED CROSS, http://www.redcrossblood.org/learn
-about-blood/blood-types (last visited Apr. 20, 2015). That is a general estimate, and some sources put the actual number of AB– individuals much lower.
See Blood Type Chart, NEW HEALTH GUIDE, http://www.newhealthguide.org/
Blood-Type-Chart.html (last updated Apr. 20, 2015).
104. See 56 Facts About Blood and Blood Donation, BLOOD CTRS. PAC.,
http://www.bloodcenters.org/blood-donation/facts-about-blood-donation
(last
visited Apr. 20, 2015).
105. There are, in fact, gay men with rare and useful blood types who
would like to donate but nevertheless are barred from doing so. Interview with
Michael Petre, Student, Univ. of Minn. Law Sch., in Minneapolis, Minn. (Mar.
30, 2014) (stating his blood type to be O–, a rare blood type usually in short
supply and among the more useful blood types in donor compatibility). Some
blood types, such as the type O–, are represented by minute portions of the
population, and individuals with those blood types have very low odds of finding a compatible donor. See Blood Type Chart, supra note 103 (showing that
Type O– individuals represent 6.5% of the population and have only a 7%
chance of finding a compatible donor).
106. See NAOMI G. GOLDBERG & GARY J. GATES, WILLIAMS INST., EFFECTS
OF LIFTING BLOOD DONATION BANS ON MEN WHO HAVE SEX WITH MEN 1–2
(2010), available at http://williamsinstitute.law.ucla.edu/wp-content/uploads/
Gates-Goldberg-MSM-Blood-Ban-Jun-2010.pdf.
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107

contributes to blood shortages. Further, though the aggregate
blood supply may generally be sufficient by some standards,
the blood supply in certain markets experiences frequent
108
shortages.
Moreover, recent studies indicate that, if the MSM lifetime
were changed to a twelve-month deferral period, 53,269 additional MSM would likely donate, leading to approximately
109
89,716 extra pints of blood in the blood supply per year. The
number increases to 130,150 additional donors and 219,200 ad110
ditional pints when the ban is lifted in its entirety. Using figures given by the American Red Cross as to how many lives one
donor can potentially save, an additional 219,200 donated pints
111
of blood translates to potentially 657,600 lives saved per year.
These numbers indicate that a total lift in the ban (not the
FDA’s proposed one-year deferral) would result in the national
112
blood supply increasing by as much as 1.4%. Such powerful
statistics demonstrate that there is a clear and tangible benefit
to allowing the MSM population to donate, without a restriction based on sexual orientation. Therefore, a better donor
guideline would attempt to increase the donor pool, and one
way to do that would be to lift the ban entirely.
That being said, the ideal policy would also protect the
blood supply from contamination. Modern medical science indicates that the problem of contamination is not nearly as dire
113
now as it was in the past. Further, medical technology has
reached a point where the current FDA gay blood ban is “anti107. Id. at 1.
108. See generally Darling, supra note 44 (explaining that blood shortages
in 2000 caused surgeries to be postponed in some major cities); 56 Facts About
Blood and Blood Donation, supra note 104 (noting that blood shortages “happen during the summer and winter holidays”).
109. GOLDBERG & GATES, supra note 106, at 2. Were the approximately 7.2
million men reporting having had another male sexual partner since the age of
eighteen allowed to donate blood, the study demonstrates that the total donations would clearly increase even if only a fraction of these men chose to donate.
110. Id. at tbl.2.
111. According to the American Red Cross, a one pint donation can save up
to three lives. Blood Facts and Statistics, AM. RED CROSS, http://www
.redcrossblood.org/learn-about-blood/blood-facts-and-statistics (last visited
Apr. 20, 2015).
112. See GOLDBERG & GATES, supra note 106, at 2 (“While these increases
in the blood supply may seem modest, they would occur in an environment
where blood supply shortages are common.”).
113. See Mohney, supra note 11 (arguing that the ban is “outdated in light
of medical advances that can detect HIV in donated blood in nearly all blood
donations” (emphasis added)).
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quated” and does little else than keep potential units of viable
114
blood from entering the blood supply. While the FDA and
blood banks had no way of detecting HIV in the blood prior to
March of 1985, technology has advanced to the point where all
blood is routinely screened for various diseases including
115
HIV. Further, given the uses of the NAT test, ten days to two
weeks is the approximate amount of time it takes to detect HIV
116
in the blood following initial infection. Taking medical developments into account, the current policy is outdated and should
be replaced by one that falls more in line with available technology.
2. Preserving the Dignity of All Citizens
Finally, the FDA should strive to protect the dignity of
United States citizens, in this case, the gay male population.
The word “dignity” should not only be taken to mean freedom
from embarrassment in this circumstance, but should include
acting on moral impulses that contribute to societal good. Take,
for example, David Dassey, a healthy, HIV-negative 62-year-old
117
gay man. Dassey experienced first-hand the Boston Marathon
terrorist attacks as a participant in the race and, despite the
dire circumstances, devastation, and loss of life, he was unable
118
to donate blood to save lives in the midst of that crisis. The
ban was enforced even in emergency circumstances. Experiences like Dassey’s are not uncommon. Whether out of a sense of
duty or during times of crisis, gay men nationwide are being
denied the chance to save lives due to a guideline the American
119
Medical Association claims is “discriminatory.” Again, there
are many gay men with useful and rare blood types who are not
120
allowed to donate, despite being perfectly healthy.
Taken as a whole, the FDA’s gay blood ban is yet another
policy that excludes a minority segment of the population from
participating in activities based not on their illness or level of
risky behavior, but rather on an inherent trait that exists inde121
pendently of risk. Even the proposed one-year deferral would
114. See id.
115. See Darling, supra note 44.
116. Id.
117. Id.
118. Id.
119. See Mohney, supra note 11.
120. See supra note 105 and accompanying text.
121. Despite FDA statements to the contrary, see FDA Guidelines, supra
note 7, the FDA ban excludes based on sexual orientation and not on the riskiness of sexual behavior. See supra note 5 and accompanying text.
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122

have a similar effect. Therefore, the ideal policy would take
into account the dignity of the MSM population while simultaneously ensuring an adequate, clean blood supply. Given the
current state of medical technology, such a solution (that does
not involve a qualification based on or affecting sexual orientation) is viable.
B. THE ADMINISTRATIVE PROCEDURE QUANDARY
Historically, the procedural challenge to the ban was the
123
most popular. Though the FDA has the power to regulate the
nation’s blood supply, all regulations must conform to federal
124
guidelines on agency rulemaking governed by the APA. In order for proposed rules to have a binding effect, general notice of
the proposed rule must be published in the Federal Register,
and must include specific information for disclosure to the pub125
lic (this is widely known as notice-and-comment rulemaking).
Exceptions to this rule apply (1) when the agency intends the
rule to be an interpretive rule, general statement of policy, or
other policy that does not bind the public, or (2) if the agency
for “good cause” finds that notice and comment procedures are
126
impracticable or unnecessary. The courts construe these exceptions narrowly and only recognize them reluctantly so as to
127
preserve the public benefit of the statute. Therefore, any federal agency rulemaking that fails to satisfy the notice-andcomment procedure and fails to satisfy either of the two exceptions—nonbinding intent or good cause—is not binding on the
public.
Recent developments have prompted the FDA to consider
altering, but not rescinding the ban, which renders a lengthy
procedural discussion moot. However, this Note will briefly discuss prior scholarship to both give legal context to the old procedural argument, and to demonstrate why such a challenge
would never have been a sufficient means by which to perma122. One medical expert states, “The one-year deferral notion constitutes
symbolic progress, but is not any more warranted than a lifetime ban.”
Scheller & Almendrala, supra note 84.
123. See generally Casey, supra note 34 (challenging the procedural validity of the ban). That viability, however, has been severely undermined by the
fact that the FDA has now initiated the notice-and-comment process in order
to change the lifetime ban to a one-year deferral period. See FDA Statement,
supra note 66.
124. See 5 U.S.C. § 553 (2012).
125. See id. § 553(b).
126. See id. § 553(b)(A)–(B).
127. Anthony, supra note 93, at 1323.
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128

nently overturn the ban. Subsection 1 briefly discusses the
(now outdated) procedural attack on the ban, and Subsection 2
addresses the insufficiency of a procedural challenge alone.
1. A Now-Defunct Procedural Challenge
Many argue that the FDA did not properly publish the
MSM guideline. The closest it has come to a formerly published
regulation regarding MSM donors only applied to those who
were free from “any disease transmissible by blood transfusion,
129
insofar as can be determined by history and examinations.”
Other than this, no regulation conforming to the procedural
guidelines of § 553 of the APA pertain to the exclusion of par130
ticular groups, including the MSM population. Prior scholarship has established that the current policy was implemented
without notice and comment, so it is not necessary to rehash in
131
detail that which has already been established.
Similarly, the old ban did not meet either exception. The
regulation was never promulgated as a permanent one; it was
accepted by the general population and blood banks with the
132
assurance that it was only a temporary fix. Public discourse
clearly accounted for very little in the events that led to institution of the permanent ban. Due to the controversial nature of
the ban and the highly un-democratic manner in which it was
enacted, the FDA likely has no defense for its guideline under
the good cause exception. In addition, the FDA has never indi133
cated that the policy is meant to be non-binding. With no protection from either exception, the gay blood ban would have
likely been struck down by the courts as an improperly implemented legislative rule if challenged before the FDA’s Decem134
ber 2014 announcement.

128. And, therefore, why any future challenge to the ban likely cannot rest
on a procedural or administrative challenge alone, if at all.
129. Casey, supra note 34, at 562 (citing 21 C.F.R. § 640.3(b)(6) (2004)).
130. See id.
131. See id.
132. See id. at 555.
133. See id.
134. See id. at 567. Casey comes to the same conclusion, arguing that the
rule “lacks a proper procedural foundation.” Id.
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135

2. One Step Further

Proponents of the gay blood ban possibly have one weapon
136
in their arsenal: the Paralyzed Veterans doctrine. While the
applicability of this doctrine to the FDA ban is only theoretical,
it could potentially obfuscate any unilateral attempt by the
FDA to alter or rescind the current ban. Having promulgated
the gay blood ban pursuant to authority granted it by federal
137
statute, the FDA could, without interference by the courts,
rescind the ban under the same authority. However, under
Paralyzed Veterans, the FDA could only change its interpretation of its rule on who may donate blood “as it would formally
modify the regulation itself: through the process of notice and
138
comment rulemaking.” This would be yet another obstacle to
139
rescinding the ban, if the doctrine applied.
That would be a tenuous argument at best, since it would
require a preliminary finding that the ban is an interpretative
140
rule, an unlikely outcome. Second, the doctrine will soon undergo scrutiny at the United States Supreme Court, since there
141
is currently a circuit split on the matter. Ultimately, because
a court would very likely find the gay blood ban to be legislative, the Paralyzed Veterans doctrine would have no applicability. Either way, supporters of the ban now only have the noticeand-comment rulemaking process as a means by which to try
135. Immediately prior to the publishing of this Note, the Supreme Court
struck down the Paralyzed Veterans doctrine. See Perez v. Mortgage Bankers
Ass’n, 135 S. Ct. 1199, 1206 (2015) (“The Paralyzed Veterans doctrine is contrary to the clear text of the APA’s rulemaking provisions, and it improperly
imposes on agencies an obligation beyond the ‘maximum procedural requirements’ specified in the APA.” (emphasis in original) (citation omitted)). This
decision does not meaningfully impact the formerly defective legitimacy of the
ban, nor does it affect the ultimate analysis or proposal of this Note.
136. Paralyzed Veterans of Am. v. D.C. Arena L.P., 117 F.3d 579, 586 (D.C.
Cir. 1997) (holding that agencies must go through notice-and-comment to
change their interpretations of regulations).
137. See supra note 35.
138. Paralyzed Veterans, 117 F.3d at 586.
139. Alternatively, an opponent of the ban could argue that the current policy is in violation of Paralyzed Veterans insofar as it adds the MSM population
to existing rules on who can and cannot donate.
140. See Paralyzed Veterans, 117 F.3d at 586. If the Supreme Court were to
uphold the doctrine, then interpretative rules would necessarily undergo formal notice-and-comment procedures every time an agency wished to change
its interpretation of an already-implemented rule.
141. See Brief for Petitioners at i, Nickols v. Mortgage Bankers Ass’n, (No.
13-1052), 2014 WL 4181711, at *1, petition for cert. granted, No.13-1052, 2014
WL 834024 (June 16, 2014). For the D.C. Circuit opinion that was challenged
and subsequently reversed, see Mortgage Bankers Ass’n v. Harris, 720 F.3d
966 (D.C. Cir. 2013).
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and keep the ban in place. Paralyzed Veterans would likely not
serve either opponents or proponents, given recent developments and the fact that the FDA will soon utilize the proper
tools to potentially change the ban.
Prior scholarship does provide an argumentative frame142
work by which the ban may be defeated in the courts, but the
arguments, though persuasive, do not go far enough in addressing the underlying issues of the gay blood ban. At any rate, these arguments are more or less outdated in light of the FDA’s
143
decision to reconsider the lifetime ban.
While the procedural challenge to the FDA’s ban is a significant step in the right direction, it does not take into account
the underlying issue of constitutionality. Even if a court were to
hold that the policy is non-binding on the public, this would
speak nothing of whether the blood ban violates the federal
144
Constitution. As briefly discussed before, if the FDA ban were
overturned on procedural grounds, that result alone would not
speak to the law’s substance, only the manner in which it was
created.
Further, the FDA is now in the process of implementing a
similar discriminatory policy following appropriate administra145
tive procedure. If the policy alteration is implemented properly, a procedural challenge to the new policy would be an exercise in futility. Therefore, a proper challenge to the blood ban
must push any procedural arguments to the backburners, so to
speak, in favor of an argument that speaks directly to the ban’s
validity—a constitutional challenge.
C. THE CONSTITUTIONAL INQUIRY
As the FDA’s gay blood ban has not been formally challenged in court on constitutional grounds, there is no case law
directly on point that may inform this analysis. Nevertheless,
constitutional law is now the best and most viable option for
having the current ban or proposed one-year deferral overturned.

142. See generally Casey, supra note 34 (challenging the procedural validity of the ban).
143. The premise of Casey’s article does predict that the FDA could reduce
the ban to a one-year deferral period. However, it fails to take into account any
constitutional arguments in favor of overturning the ban. Id.
144. Specifically, the Fifth Amendment. U.S. CONST. amend. V. See discussion infra Part II.C.1.
145. See Scheller & Almendrala, supra note 84.
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The FDA ban explicitly identifies and applies to a particu146
lar population—gay men—as a class. To that effect, the Due
147
148
Process Clause and Equal Protection Clause are each potentially relevant to the analysis, though pursuing one may
yield more favorable results to litigants than the other. Ultimately, this Note seeks to conclude which of the two doctrines
would better serve litigants seeking to invalidate the blood ban,
and will follow the line of analysis best suited to overturning
the ban on the basis of its unconstitutionality.
In the past, the Due Process Clause and the Equal Protection Clause were treated very differently, and courts emphasized that the Fifth Amendment contained no equal protection
149
provision. However, while courts still hold that the Fifth
Amendment does not contain an Equal Protection Clause per
150
se, current interpretation reflects otherwise. The Supreme
Court has gone as far as to state that “the concepts of equal
protection and due process, both stemming from our American
ideal of fairness, are not mutually exclusive . . . discrimination
151
may be so unjustifiable as to be violative of due process.”
Thus, either Equal Protection or Due Process can be used to
challenge the FDA’s gay blood ban (or the potential one-year
deferral).
Subsection 1 discusses a challenge under the federal Due
Process Clause. Subsection 2 delves into the federal Equal Protection doctrine, which ultimately may be the better basis for a
challenge to the ban. Subsection 3 brings the analysis to its
conclusion, and ultimately, this Section concludes that the gay
blood ban (and the proposed one-year deferral) is not constitutional as it applies to the MSM population.
1. Due Process
The Fifth Amendment’s Due Process Clause states that
“No person shall . . . be deprived of life, liberty, or property,
152
without due process of law . . . .” The Due Process Clause, un146. See FDA Guidelines, supra note 7 (noting that the ban applies to “men
who have had sex with other men”).
147. U.S. CONST. amend. V (“No person shall be . . . deprived of life, liberty,
or property, without due process of law . . . .”).
148. U.S. CONST. amend. XIV, § 1 (“No State shall . . . deprive any person
of life, liberty, or property, without due process of law, nor deny to any person
within its jurisdiction the equal protection of the laws.”).
149. See United States v. Carolene Products Co., 304 U.S. 144, 151 (1938).
150. See Bolling v. Sharpe, 347 U.S. 497, 499 (1954).
151. Id.
152. U.S. CONST. amend. V.
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like the Fourteenth Amendment, applies to the federal government, so application to the FDA gay blood ban is appropriate without rehashing in detail the analysis in Bolling v.
153
Sharpe. Potentially discriminatory laws—those that curtail
personal liberty of a class—are properly analyzed under the
Fifth Amendment. Discrimination, if it is unjustifiable, may vi154
olate the Due Process Clause. Specifically, the FDA ban, like
any other potentially discriminatory law, would be challenged
as violating substantive Due Process, as opposed to procedural
155
Due Process.
A substantive Due Process challenge will stand if it affects
or unduly burdens a property or liberty interest, but courts do
156
not treat all interests the same. If a law affects a fundamental liberty or right, then it will be subjected to strict scrutiny
and upheld only if the law is necessary and narrowly tailored to
157
achieve a compelling government interest.
Otherwise, the
lesser “rational basis” standard would apply, and courts are
158
very unwilling to disturb laws under this standard. Thus,
whether the gay blood ban or a one-year deferral would pass
constitutional muster under a Due Process analysis depends on
whether it affects a fundamental “liberty” or right.
153. Bolling, 347 U.S. at 497. The analysis in Bolling is more relevant to,
and will be discussed in, the following section on Equal Protection. See discussion infra Part II.C.2. But for the purposes of Due Process, the Fifth Amendment’s Due Process Clause appropriately applies to the FDA’s regulation, being a creation of a federal agency.
154. Bolling, 347 U.S. at 499.
155. Substantive Due Process issues arise when the regulation or law itself
deprives the individual of property or liberty interests. See generally Lawrence
v. Texas, 539 U.S. 558 (2003) (discussing substantive Due Process). On the
other hand, procedural Due Process requires that “an individual be given an
opportunity for a hearing before he is deprived of any significant property interest.” Cleveland Bd. of Educ. v. Loudermill, 470 U.S. 532, 542 (1985). Thus,
the issue in a procedural Due Process analysis is whether the victim was afforded the appropriate hearing or process due under the law. Id. And while, in
theory, a procedural Due Process claim could have potentially been made
against the FDA for the improperly implemented lifetime ban, supra Part II.B,
such an argument is tenuous and likely irrelevant in light of recent developments.
156. See, e.g., United States v. Windsor, 133 S. Ct. 2675, 2695 (2013) (“The
liberty protected by the Fifth Amendment’s Due Process Clause contains within it the prohibition against denying to any person the equal protection of the
laws.”).
157. See Planned Parenthood v. Casey, 505 U.S. 833, 929 (1992).
158. See Romer v. Evans, 517 U.S. 620, 631 (1996) (“[I]f a law neither burdens a fundamental right nor targets a suspect class we will uphold the legislative classification so long as it bears a rational relation to some legitimate
end.”).
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The term liberty as it applies to the Due Process Clause enjoys a liberal interpretation, encompassing “the full range of
159
conduct which the individual is free to pursue.” Surely donating blood—contributing to the nation’s blood supply and thus
national health—is more than a casual activity. For some, the
act of donating blood is a serious moral obligation. At the very
least, the act of donating contributes to a utilitarian “greater
good,” that of keeping the nation’s blood supply at adequate
160
levels. Donating blood is a serious act of giving, even potentially life-saving, that requires a great deal of contemplation,
and thus a court may reasonably find that donating blood may
fall into the “full range” of personal conduct individuals are free
161
to pursue.
Assuming that donating blood is a liberty under the Due
Process Clause, then no law may impede this liberty unless
162
pursuant to a rational governmental objective. Further, if the
163
law is restrictive, it must not be an “arbitrary deprivation.”
Because the FDA ban applies to MSM as a class, it would most
likely be subjected to some form of heightened scrutiny in
164
court. The government interest is legitimate—the protection
of our nation’s blood supply from HIV/AIDS was the genesis of
165
the law—and for a while it was the best method of doing so.
However, the scientific and political landscape of our nation
166
has changed since the regulation was implemented. New
methods of HIV detection are available, methods that are faster
and more accurate than those available at the time of the
167
ban. Thus, the FDA’s regulation is not narrowly tailored to
achieve what it sets out to do, but rather, only rests upon “hypothetical justifications” that are incorrect in light of current
168
science and medicine.

159. Bolling, 347 U.S. at 499. This “free range” of conduct encompasses
more than mere freedom from “bodily restraint.” It implicates the freedom
from government interference in daily life, absent a proper governmental objective. Id. at 499–500.
160. This is especially so given recent concerns over blood shortages in major cities. See infra note 197.
161. Bolling, 347 U.S. at 499.
162. See id. at 499–500.
163. See id. at 500.
164. See infra note 211 and accompanying text.
165. See supra Part I.A.
166. See supra Part I.B.
167. Darling, supra note 44.
168. See Bostic v. Schaefer, 760 F.3d 352, 377 (4th Cir. 2014).
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However, this brief analysis is contingent on the assumption that a court would view donating blood as either a property
or liberty interest. Currently, no cases or legal authority speak
to whether donating blood is a liberty or property interest.
There is much less doubt as to whether donating blood is a
fundamental right. And because a successful Due Process challenge hinges on the infringement of a right, this argument is
likely the weaker one. And if a court wishes to avoid the arduous task of justifying a holding that donating blood is a fundamental right, it could merely bypass that inquiry by stating the
FDA’s policy doesn’t even pass a rational basis test.
The Supreme Court has acknowledged that the Due Process Clause does not necessarily provide as much protection as
169
Equal Protection. As the Court has long held that the explicit
guarantee of Equal Protection in federal law applies to the
Fourteenth Amendment, and given that classifying blood donation is a tenuous argument, Due Process is likely the “lesser” of
the two potential avenues by which to challenge the FDA’s donation policy.
2. Equal Protection
In principle, the Equal Protection Clause speaks to the issue presented in the gay blood ban, that is, whether equity
should limit the differential treatment gay and bisexual men
170
receive based on their differences from heterosexual men. It
has been established that heterosexual women, gay women,
171
and heterosexual men are not the target of the ban. The decision in Bolling and its progeny long ago established that there
is an Equal Protection component incorporated into the Due
Process Clause of the Fifth Amendment, thus affording citizens
of the United States greater protection under federal law as
172
well as state law.
169. Adarand Constructors, Inc. v. Pena, 515 U.S. 200, 213 (1995) (“Although this Court has always understood [the Due Process Clause] to provide
some measure of protection against arbitrary treatment by the Federal Government, it is not as explicit a guarantee of equal treatment as the Fourteenth
Amendment . . . .”).
170. See generally Derek W. Black, The Constitutional Limit of Zero Tolerance in Schools, 99 MINN. L. REV. 823, 868 (2015) (“[E]quity limits differential
treatment based on immutable, illegitimate, or irrational differences between
individuals.”).
171. See supra Part I.B.
172. Specifically, the court in Bolling held that “the concepts of equal protection and due process, both stemming from our American ideal of fairness,
are not mutually exclusive . . . [D]iscrimination may be so unjustifiable as to
be violative of due process.” Bolling v. Sharpe, 347 U.S. 497, 499 (1954). See
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Since Romer v. Evans, courts generally accept the idea that
homosexuals as a class fall under the protection of the Equal
173
174
Protection Clause. Since the decision in Lawrence v. Texas,
which struck down sodomy laws specifically targeted at same175
sex couples, courts have extended more protection to homosexuals as a class. This trend continued in the recent United
States v. Windsor decision, in which the Supreme Court held
that marriage laws defined exclusively in the context of hetero176
sexual unions were unconstitutional. It follows that any law
that either facially discriminates against the LGBT population
or has the effect of discriminating against them would be subject to an Equal Protection analysis.
The Equal Protection analysis is the more effective challenge to the FDA’s gay blood ban, and this requires a deeper
analysis. Subpart (a) will examine the discriminatory effect (if
not purpose) the policy has on the MSM population. Subpart (b)
will discuss how the overinclusiveness of the policy affects the
effectiveness and legitimacy of the policy’s goals. Finally, Subpart (c) discusses the appropriate level of scrutiny that would
apply to the policy in an Equal Protection Challenge.
a. Whether the FDA’s Policy Has a Discriminatory Effect on
the MSM Population
The primary issue with using Equal Protection is that the
FDA policy, either in its current form or its proposed form, does
177
not specifically address homosexual or bisexual men. Thus
one may argue that, under Romer, the FDA’s policy does not
target a protected class. However, the analysis does not end
there. Courts have widely held that facially neutral laws which
have discriminatory effects or impacts on protected classes will
178
also be subject to an Equal Protection analysis. The FDA’s
blood ban, either in its current form or under the proposed oneyear deferral, falls under the classification of laws that are not

also Korematsu v. United States, 323 U.S. 214, 235–36 (1944).
173. See Romer v. Evans, 517 U.S. 620, 631 (1996) (“[I]f a law neither burdens a fundamental right nor targets a suspect class, [the court] will uphold
the legislative classification so long as it bears a rational relation to some legitimate end.”).
174. 539 U.S. 558 (2003).
175. Id. at 579.
176. See United States v. Windsor, 133 S. Ct. 2675, 2695 (2013).
177. See FDA Guidelines, supra note 7.
178. See, e.g., Vill. of Arlington Heights v. Metro. Hous. Dev. Corp., 429
U.S. 252, 259 (1977).

2390

MINNESOTA LAW REVIEW

[99:2363

facially discriminatory but which have a discriminatory ef179
fect.
The FDA policy explicitly prohibits men who have had sex
180
with men since 1977 from donating blood. In practical terms,
this could cover heterosexual, bisexual, and homosexual men.
However, the law largely impacts gay men, the very population
181
that was associated with the HIV/AIDS epidemic. In addition,
the FDA’s MSM policy was specifically implemented to address
182
concerns over HIV/AIDS. Gay and bisexual men inevitably
represent a tremendous portion of the MSM population, and for
all intents and purposes define the MSM population.
The law’s discriminatory impact does not change even if
the FDA’s recommended one-year deferral period is implemented, because it also uses the MSM population as a starting point
by which to weed out potential risky blood donors. For many
gay men, the FDA’s proposed new policy is just as prohibitive
as the old one. To put it another way, “[t]he FDA has decided
that the blood coursing through your veins isn’t a lifetime
183
threat to the American public—just a year-long threat.” The
one-year deferral would do little to change that perception. In
fact, maintaining a ban in some form effectively perpetuates
negative stereotypes and stigmas attached to gay and bisexual
184
men by basing donor guidelines on stereotypes, not science.
The discriminatory effect and intent are more pronounced
185
when available science is taken into consideration. The current ban and proposed one-year deferral are (and would be)
written in such a way to suggest some discriminatory or sexual
179. These laws are also illegal. See generally Yick Wo v. Hopkins, 118 U.S.
356 (1886) (holding that a law, even if facially neutral, may impose purposeful
discrimination if it is administered in a discriminatory way).
180. FDA Guidelines, supra note 7.
181. See supra Part I.A.
182. See supra Part I.B.
183. John Gallagher, Nine Ways To Avoid Sex for the Next Year So You Can
Donate a Pint of Blood, QUEERTY (Dec. 31, 2014), http://www.queerty.com/
nine-ways-to-avoid-sex-for-the-next-year-so-you-can-donate-a-pint-of-blood
-20141231 (“[T]o donate blood, you need to get ready now, which means giving
up sex for a year.”).
184. Andrew Cray, Members of Congress Encourage End to Discriminatory
Blood Donation Policy, THINKPROGRESS (Aug. 5, 2013), http://thinkprogress
.org/lgbt%20/2013/08/05/2412721/msm-blood-donation.
185. Id. (“The absence of a non-discriminatory rationale becomes even
clearer in light of significant advancements in medical technology and developments in blood screening and record-keeping since the donation ban was put
in place 30 years ago. In fact, current blood screening tests are so effective
that the probability of HIV transmission through blood transfusion is one in
1.5 million, a significant decrease from risk levels in the mid-1990s.”).
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orientation-based animus. Further, the policies are part of
larger fear-based policy-making in response to the HIV/AIDS
186
epidemic. The gay blood ban in any form does not likely fall
under the type of laws that make classifications serving to protect legitimate interests, especially given the science that has
187
developed since the ban was first implemented.
With all factors taken into consideration, including the history of the HIV/AIDS epidemic, the FDA’s initial response by
188
way of targeting homosexual men, and this discussion, a
court would very likely find both the gay blood ban and the
proposed one-year deferral to have a discriminatory effect. Further, there is a reasonable chance that a court would find it (either the current ban or one-year proposal) to have a discriminatory intent, despite the wording of the policy.
b. Whether the FDA’s Policy Is Overinclusive
Any time a law is challenged, the government may deflect
the suit by proving the law is appropriately tailored to further
189
some interest. The FDA would likely argue that the gay blood
190
ban meets that criterion under any level of scrutiny. However, one crucial counterargument would be that the ban is
overinclusive.
A law is overinclusive if it applies to all people who are
similarly situated, but also people who should not be included;
essentially, the law regulates more people than is necessary to
191
achieve the government’s purported interest. Under either a
192
rational basis or strict scrutiny test,
some laws are so
underinclusive (not regulating enough individuals to accomplish government objective) or so overinclusive in their classification that the distinction “cannot be said” to rationally further
193
the posited state interest.
186. Id.
187. See Nordlinger v. Hahn, 505 U.S. 1, 13 (1992).
188. Casey, supra note 34, at 554–56.
189. See Ry. Express Agency, Inc. v. New York, 336 U.S. 106, 112 (1949)
(Jackson, J., concurring) (“The burden should rest heavily upon one who would
persuade us to use the due process clause to strike down a substantive law or
ordinance.”).
190. See infra Part II.C.2.c for a discussion of the standards of scrutiny
courts apply to these types of constitutional challenges.
191. Equal Protection Definition, LEGAL DICTIONARY, http://legal
-dictionary.thefreedictionary.com/Equal+Protection (last visited Apr. 20,
2015).
192. See Nordlinger, 505 U.S. at 10 (discussing the rational basis and strict
scrutiny standards).
193. Id. at 35 (Stevens, J., dissenting).
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If a law is overinclusive, specifically, a court will invalidate
it if it “sweeps too broadly and operates too indiscriminately” in
194
furthering the state’s interest or objectives. As Justice Stevens wrote, “[i]t is just short of absurd to conclude that the legitimate state interest in [regulating] a relatively small number” of risky individuals is rationally furthered by regulating a
195
significantly wider population.
Blood banks’ opposition to the FDA’s gay blood ban illus196
trates this principle. The American Red Cross, for example,
has publicly argued against the lifetime ban on the grounds
197
that it contributes to blood shortages. The inability to collect
the blood of millions of MSM, while not the sole cause of any
blood shortage, is a contributing factor in the critical problem of
198
the blood shortage. As has already been discussed, while the
blood supply in the aggregate is not in shortage, this speaks
199
nothing of the potential for rare blood-type shortages. Also
recall that opening the pool of donors to gay men is estimated
200
to save an upwards of 657,600 lives saved per year. All told,
the ban does prevent a small portion of a high-risk population
from donating, but also excludes thousands of otherwise viable,
healthy donors.
The biggest factor in the ban’s overinclusiveness is developing technology. When the ban was first implemented, and little
was known about HIV, that might have not been the case. But
as science and society have evolved, the pool of donors at risk
201
for HIV infection has narrowed. The fact that thirty-seven
202
states (and counting) now allow gay marriage has significant194. Id.
195. Id. at 36–37 (drawing that conclusion as applied to property taxes in
California).
196. It is estimated that, in any given year, more than seven million men
are prohibited from ever donating blood. Casey, supra note 34, at 567. This is
not surprising, however. As has been discussed, the concern over blood shortage has always been the primary objection of blood banks to the FDA policy.
See Dorney, supra note 36, at 144.
197. See Darling, supra note 44 (“In 2000, [blood] shortages led to postponements of elective surgeries in Philadelphia, Atlanta, and Los Angeles. At
the time, all hospitals combined needed about 80,000 units of blood daily, but
the Red Cross could deliver only 36,000.”). Id.
198. 56 Facts About Blood and Blood Donation, supra note 104 (“[I]f only
one more percent of all Americans would give blood, blood shortages would
disappear for the foreseeable future.”).
199. See supra Part II.A.1.
200. See Blood Facts and Statistics, supra note 111 (finding that a one pint
donation can potentially save up to three lives a year).
201. See supra Part I.B.
202. See States, FREEDOM TO MARRY, http://www.freedomtomarry.org/
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ly changed society’s perception of the LGBT community. There
is a discrete group of individuals whose behavior puts them at
risk, including IV drug users and sharers and those who indis203
criminately have unprotected sex.
Those groups and the
MSM population are not mutually inclusive, though the policy
implications of the FDA’s ban would seem to suggest otherwise.
Whether or not the FDA’s gay blood ban is overinclusive is
not wholly dispositive of the constitutional issue. Courts apply
various standards of scrutiny when laws are challenged under
the Equal Protection Clause, and under the same facts, one
standard will yield more favorable results than the other. The
overinclusiveness of the ban is thus tied closely with the standard of scrutiny that would likely apply.
c. The Appropriate Standard of Scrutiny
Though Equal Protection is likely the more effective of the
two potential constitutional challenges, courts apply varying
standards of scrutiny when analyzing such challenges and the
outcome depends heavily on which standard the court chooses
to use. Essentially, “unless a classification warrants some form
of heightened review because it jeopardizes exercise of a fundamental right or categorizes on the basis of an inherently suspect characteristic, the Equal Protection Clause requires only
that the classification rationally further a legitimate state in204
terest.”
The least stringent level of scrutiny is known as rational
basis, and a law challenged as violating the Equal Protection
Clause will survive under an Equal Protection analysis if it is
205
rationally tailored to further a legitimate state interest. This
standard is more widely used, and will only be discarded for
heightened scrutiny if a state-imposed classification “warrants
some form of heightened review because it jeopardizes exercise
of a fundamental right or categorizes on the basis of an inher206
ently suspect characteristic.”
Strict, or heightened, scrutiny applies where courts find
the question to be one of equal protection against infringement
of fundamental rights or discrimination against suspect clas207
ses. Under the strict scrutiny standard, a law “may be justistates (last updated Mar. 4, 2015).
203. See infra Part III.B.
204. Nordlinger v. Hahn, 505 U.S. 1, 10 (1992).
205. Id.
206. Id.
207. See generally United States v. Windsor, 133 S. Ct. 2675, 2716–17
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fied only by compelling state interests, and must be narrowly
208
drawn to express only those interests.” Further, the government bears the burden of satisfying the standard, and must rely on the law’s actual purposes, rather than hypothetical justi209
fications to prevail. Having historically been applied to cases
210
of race and national origin discrimination, the idea of subjecting classifications based on sexual orientation to strict scrutiny
211
has grown popular in recent years.
The Second Circuit explicitly endorsed this line of thought
by applying strict scrutiny to classifications based on sexual
212
orientation. When that decision made its way to the Supreme
Court in United States v. Windsor, the Court flirted with the
idea of applying strict scrutiny and, though it ultimately did
not explicitly affirm the use of that standard, nevertheless af213
firmed the Second Circuit’s ruling in its entirety. The Fourth
Circuit applied strict scrutiny recently to a same-sex marriage
case, though the court did so because it held marriage to be a
214
fundamental right. Even though strict scrutiny was not applied on the basis of sexual orientation being a suspect class,
215
the court nevertheless came close to doing so. The Tenth Circuit has also applied strict scrutiny to cases involving same-sex
216
couples.
The trend is clear: though the Supreme Court has not explicitly used a strict standard of review for classifications based
on sexual orientation, its shifting attitude indicates that such a
standard may become an eventuality, though not an inevitability. It is doubtful, though within the realm of possibility, that a
federal court would decline to use at least some form of heightened scrutiny in analyzing a law such as the FDA’s blood donation policy.

(2013) (discussing when strict scrutiny should apply).
208. Bostic v. Schaefer, 760 F.3d 352, 377 (4th Cir. 2014) (quoting Carey v.
Population Servs. Int’l, 431 U.S. 678, 686 (1977)) (internal quotation marks
omitted).
209. Id. (citing Fisher v. Univ. of Tex. at Austin, 133 S. Ct. 2411, 2420
(2013); Shaw v. Hunt, 517 U.S. 899, 908 n.4 (1996)).
210. See, e.g., Adarand Constructors, Inc. v. Pena, 515 U.S. 200, 222 (1995).
211. President Obama in particular is an advocate of applying the heightened scrutiny standard to cases involving sexual orientation discrimination.
See Windsor, 133 S. Ct. at 2683.
212. Id. at 2684.
213. Id. at 2696.
214. Bostic v. Schaefer, 760 F.3d 352, 375 (4th Cir. 2014).
215. Id. at 375 n.6.
216. See Kitchen v. Herbert, 755 F.3d 1193, 1218 (10th Cir. 2014).
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A strict-scrutiny analysis would very likely yield favorable
results to those seeking to have the gay blood ban or one-year
deferral overturned. The FDA may repeat its argument that
the MSM population is more at risk of transmitting HIV/AIDS,
but this argument would be unavailing, as the FDA “cannot
rest upon a generalized assertion as to the classification’s rele217
vance to its goals.” In short, the “purpose of the narrow tailoring requirement [in a strict-scrutiny analysis] is to ensure that
the means chosen fit the compelling goal so closely that there is
little or no possibility that the motive for the classification was
218
illegitimate.”
As already discussed, the FDA’s current gay blood ban and
proposed one-year deferral are, as they relate to the goal of
blood supply safety, impermissibly overinclusive. So under a
strict-scrutiny analysis, the FDA would likely fail to persuade
the court to uphold the constitutionality of the gay blood ban. If
any viable and less discriminatory option for the FDA exists,
then the court would especially look at the blood ban with a
wary eye.
3. Constitutional Conclusions
The government objective of defending the blood supply
must remain stalwart, yet this does not save the FDA’s gay
219
blood ban or one-year deferral. With the advent of new technologies and a greater understanding of HIV, the ban is no
longer narrowly tailored to achieve a compelling government
220
interest, but now is considered by many, including medical
221
222
experts, to be arbitrary and based on obsolete science.
The landmark decision in Windsor struck down the most
223
restrictive portion of DOMA. Gay marriage is now legal in
217. Id. (quoting Richmond v. J.A. Croson Co., 488 U.S. 469, 500 (1989))
(internal quotation marks omitted).
218. Id. (quoting Grutter v. Bollinger, 539 U.S. 306, 333 (2003)) (internal
quotation marks omitted); see also id. (stating that only “the most exact connection between justification and classification” would survive strict scrutiny
(quoting Gratz v. Bollinger, 539 U.S. 244, 270 (2003) (internal quotation
marks omitted)).
219. This is especially true since the law is now based on scientific facts
which have ceased to exist and have been replaced by newer understanding of
the disease. See Scheller & Almendrala, supra note 84.
220. See United States v. Windsor, 133 S. Ct. 2675, 2717 (2013). The “narrowly tailored” law achieving a “compelling government interest” is the hallmark standard by which a law may survive the strict scrutiny standard. Id.
221. See Mohney, supra note 11.
222. See id.
223. See Windsor, 133 S. Ct. at 2695–96.
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224

thirty-seven states. That two men may legally marry yet be
considered a high risk of HIV is not patently absurd, but the
idea of monogamy between same-sex couples is now a socially
(and in places, legally) recognized relationship, a far cry from
the environment of the 1980’s. The FDA blood ban (and potential deferral) does not address MSM who are in monogamous
relationships and does not consider them to be low-risk indi225
viduals. With the changing attitudes towards homosexuality,
same-sex marriage, and new technology, including the NAT
226
and antibody tests, there is no justification, constitutional or
otherwise, for maintaining the gay blood ban as it is.
Further, the guideline is likely violative of the federal
Equal Protection Clause. While this Note cannot make a definitive conclusion as to the outcome of a constitutional challenge
to the FDA’s gay blood ban or one-year deferral, a successful
challenge would very likely include arguments that the law,
though facially neutral, has a discriminatory effect on gay and
bisexual men as a protected class and is impermissibly
overinclusive as to be violative of the Equal Protection Clause.
III. POTENTIAL EQUITABLE SOLUTIONS
The challenge to the FDA’s gay blood ban set forth in this
Note is a comprehensive, direct challenge to the ban. It proposes a method by which the ban may be properly challenged, di227
rectly in courts. By challenging the ban on the basis of its
constitutional merits, this Note lays the groundwork for challenging the ban directly. An indirect challenge would not be
228
sufficient, as it would not address the ban on its merits. Proving the unconstitutionality of the ban is, however, only one of
this Note’s ultimate goals. Pointing out the unconstitutionality
of the current and future policy has little utility without suggesting an ideal policy that may be used instead. Section A
briefly considers what other countries have implemented in
terms of blood donation guidelines. Section B suggests an effective and equitable guideline.

224. See States, supra note 202.
225. FDA Guidelines, supra note 7.
226. See Darling, supra note 44.
227. See supra Part II (discussing constitutional challenges to the FDA’s
gay blood ban).
228. See Nelson, supra note 87, at 16.
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A. COMPARATIVE APPROACH: WHAT OTHER COUNTRIES HAVE
DONE
While maintaining the current gay blood ban cannot stand,
as it most likely would not withstand constitutional muster,
eliminating the ban entirely with no other guidelines may have
229
troubling consequences. After all, the rate of HIV/AIDS infec230
tions in the young MSM population is on a steady rise. However, testing technology allows banks to determine whether
blood is infected more inexpensively, more accurately, and more
231
quickly. Therefore, rather than eliminating the ban, a balance should be struck between preserving the integrity of the
nation’s blood supply and allowing certain MSM populations at
232
low risk for HIV/AIDS infection to donate blood.
One inquiry that may better inform the problem is a comparative approach—to look beyond the borders of the United
States and evaluate how other countries with less restrictive
guidelines on blood donations have handled the problem. Note
that this comparative approach is not a basis for challenging
the ban. It is a method by which to evaluate the effectiveness
(or lack thereof) of blood donation policies from other nations.
Maintaining a deferral period of a year is a popular alternative to a lifetime bar, and many countries have done just
233
that. Australia, for example, has a one-year ban in place.
Studies have shown that, for men who are sexually inactive for
a twelve-month period, there is no increased risk of transfu234
sion-transmitted cases of HIV. However, while such deferrals
are more progressive than the current United States regula235
tion, they might lead to extended “dry spells” on any MSM
229. See FDA Guidelines, supra note 7. If anything, a questionnaire would
be critical in ascertaining who may and who may not donate, so as to screen
potentially high-risk donors.
230. HIV AND YOUNG MEN, supra note 73.
231. See Kain, supra note 56.
232. Low-risk sexual behavior as defined by the FDA (e.g., not having sex
with prostitutes, not engaging in sexual activity involving intravenous drug
use, etc.) should be applied to gay men as it is applied to heterosexual individuals. A low-risk MSM may be a gay man in a monogamous marriage, whereas
a high-risk MSM may be a sex worker.
233. Seed et al., supra note 61, at 2722. A one-year deferral essentially allows gay men to donate blood if they have not had sex with other men within
the past year.
234. See id.
235. The phrase “dry spell” is a common colloquialism meaning “to go for a
period of time (usually longer than shorter) without something,” e.g., sex. Dry
Spell Definition, URBAN DICTIONARY, http://www.urbandictionary.com/define
.php?term=dry%20spell (last visited Apr. 20, 2015).
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236

who ever hopes to donate blood. And this is the primary objection to the FDA’s proposed one-year deferral period.
Other nations have implemented less restrictive laws. Declaring that “sex between people of the same sex ceases to be
considered a danger, disease, or infection by the Health Ministry,” Chile completely lifted the ban on gay and lesbian do237
238
nors. Mexico has also lifted its ban entirely. Neither ban
lifts are without qualification: Chile’s new policy bans all people, regardless of sexual orientation, from donating blood if
they have engaged in risky sexual behavior, which is defined as
239
sex with more than one partner in the last twelve months. In
Mexico, the focus is similarly on risky behavior rather than so240
cial groups. Gay and bisexual men who have a history of using condoms, who do not inject drugs, and who are not sex
241
workers are eligible to donate blood under Mexico’s new law.
242
Heterosexuals are subjected to the same standard, an important distinction from the current United States guidelines.
In the countries that have lifted the ban, there is a clear
shift in focus. Instead of identifying an individual’s sexual orientation or a specific social group, the laws focus on risky be243
haviors. In the process of updating their laws, the countries
with complete ban-lifts used compelling policy arguments in
244
regards to ending discrimination. The countries that have
ended their bans placed at least some emphasis on the rights of
minority citizens. The FDA, on the other hand, makes little
245
mention of whether its policy is discriminatory.
236. Though a year-long deferral is clearly preferable to a lifetime ban, the
practical consequences essentially restrict the sexual activity of the MSM population, especially considering that in some states, gay marriage is legal. The
hypothetical one-year deferral would lead to an unusual situation for many
MSM: abstain from sex (even if married) for a year, donate, and then resume
sexual activity.
237. Trovall, supra note 61.
238. Roberts, supra note 61.
239. Trovall, supra note 61.
240. Roberts, supra note 61.
241. Id. It should also be noted that the new law is devoid of qualifications
based on sexual identity. See id.
242. See id.
243. See, e.g., id.
244. See Sunnivie Brydum, Mexico Lifts Blood Donation Ban for Gay and
Bisexual Men, ADVOCATE (Dec. 28, 2012, 4:32 PM), http://www.advocate.com/
health/health-news/2012/12/28/mexico-lifts-blood-donation-ban-gay-and
-bisexual-men.
245. FDA Guidelines, supra note 7 (“FDA’s deferral policy is based on the
documented increased risk of certain transfusion transmissible infections,
such as HIV, associated with male-to-male sex and is not based on any judg-

2015]

BAD BLOOD

2399

Excluding the policy justification from the discriminationcontext cannot stand. As the previous section established, there
are meritorious arguments addressing the discriminatory as246
pect of the FDA ban. Thus, for a truly equitable solution to
emerge, evaluation of the ban must follow the model of countries such as Mexico and Chile and put more emphasis on eliminating discriminatory elements within any new guidelines.
B. A SAFE AND EQUITABLE POLICY SOLUTION
An ideal donation policy in the United States must maintain the integrity of the blood supply and provide equitable
treatment to the MSM community. Above all, it may not apply
in unqualified terms to one population or another in order to
247
remain consistent with Due Process and Equal Protection. As
such, this Note suggests a regulation that allows gay men who
engage in non-risky sexual behavior to donate blood while
maintaining safeguards in place to protect the blood supply.
First, the new regulation must apply to all individuals,
men and women, regardless of their sexual orientation. Such a
qualification is arbitrary and potentially unconstitutional, as
248
discussed above. To create a law that is both effective and
protects the constitutional interests of potential blood donors,
the United States should look to solutions enacted by other
249
countries, such as Chile and Mexico. Thus, the new guideline
must shift the focus from sexual orientation to sexual behav250
ior. The new regulation should take into account current
251
medicine and current blood-testing technology.
Current technology allows for the detection of HIV immediately following infection at around ten days, and two weeks is
252
considered a “safe” timeframe. Because of the timeline in
253
which HIV infection occurs and shows up in tests, all individment concerning the donor’s sexual orientation.”).
246. See supra Part II.C.
247. See supra Part II.C.
248. See supra Part II.C.
249. Roberts, supra note 61; Trovall, supra note 61.
250. For example, instead of focusing on gay men having sex, shift the focus to any individual who habitually uses intravenous drugs concurrently with
sex.
251. See Darling, supra note 44.
252. Id.
253. Id. (“Within seven to 10 days, we can say with 99.9 percent accuracy
whether or not a blood sample is HIV-positive. The chance of an HIV-positive
blood sample testing negative after the 7 to-10-day window is about 1 in 2 million . . . . [I]f you’ve had unsafe sex within the past 10 days, it might be reasonable for us to send you home. But a lifetime ban . . . is kind of ridiculous.”).
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uals who have engaged in unsafe sex within fourteen days prior
to attempted donation should be turned away. This will ensure
that gay men engaging in “safe” sex, or those who have not, will
still be eligible at some point in the foreseeable future to donate
blood. Further, it should be emphasized that rejecting donations should be the exception: individuals who have a history of
using condoms, engaging in safe sex, and who have not engaged
in unsafe sex within the past fourteen days should be permitted
254
to donate blood. This proposed process would impose no additional burden on blood banks, as they routinely pay for all blood
255
screening, using the latest technology at their disposal.
Defining what constitutes safe sexual activities is critical
to developing a sound, effective guideline. For example, unsafe
sex could constitute engaging in unprotected sex with one or
multiple partners, having sexual relations of any sort with a
sex worker, and engaging in sexual behavior in concurrence
256
with drug use. However, stipulating the number of sexual
partners one may have is, so to speak, another can of worms
that this Note shall not open. Additionally, the definition may
include stipulations regarding proper condom usage, regardless
of the sexual partner(s) involved. Such a solution, with the
fourteen-day deferral period, takes adequate steps to filter out
high-risk donors and, with the elimination of the MSM designation, does not run afoul of the due process doctrine.
Such a new regulation should also follow the proper procedural guidelines for administrative rules, pursuant to the APA,
257
so as to not make the same mistakes as the current guideline.
Specifically, the notice-and-comment requirement, critical to
preserving the public discourse on rules intended to be binding,
258
should be respected in the interest of the democratic process.
254. Either way, it would seem that the public health policy goals would
still be maintained with this regulatory framework. The most critical objective
now is to remove the stigma associated with HIV.
255. Blood banks do not only pay for HIV screening, they screen for a host
of other ailments and viruses, including hepatitis B, hepatitis C, blood that is
at risk for leukemia or neurological diseases, syphilis, West Nile Virus, and
bacterial contamination. See Donation FAQs, AM. RED CROSS, http://www
.redcrossblood.org/donating-blood/donation-faqs (last visited Apr. 20, 2015).
256. Such a definition for “unsafe” sexual activities may be taken from definitions provided in countries where the focus on donation restrictions is on
behavior rather than sexual orientation, such as Chile. See generally supra
Part III.A.
257. See generally 5 U.S.C. § 553 (2012) (articulating the rule-making procedures).
258. Cf. Anthony, supra note 93, at 1312 (“To use . . . nonlegislative documents to bind the public violates the Administrative Procedure Act . . . and
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This proposed solution is the most equitable. By basing
guidelines for who may donate on risky behavior rather than
sexual orientation, the FDA can avoid claims of discriminatory
259
policy-making. With clearly stipulated behaviors (proven to
be high-risk) that would warrant a temporary deferral from donating blood, the FDA can achieve its goals of protecting and
growing the national blood supply. The FDA would not only be
acting pursuant to an unquestionably constitutional regulation,
but one that increases the availability of blood and protects the
dignity of the MSM population.
All of this being said, this Note includes a proposal for
what a new blood donation guideline might contain. Currently,
the language of the FDA’s rule states that:
Men who have had sex with other men (MSM), at any time since 1977
(the beginning of the AIDS epidemic in the United States) are currently deferred as blood donors. This is because MSM are, as a group,
at increased risk for HIV, hepatitis B and certain other infections that
260
can be transmitted by transfusion.

Even the new regulation, with its one-year deferral period,
looks to contain the exact same language, which substantively
261
changes nothing about the discriminatory impact on gay men.
This language must be eliminated in its entirety, as sexual orientation is an arbitrary method of determining risk.
Instead, the new regulation should begin with language
such as: “Individuals who have engaged in sexual behavior
characterized as risky, unsafe, or dangerous are currently deferred as blood donors.” Removing a label regarding gender,
sex, or sexual orientation is crucial in ensuring that the new
rule applies equally to all citizens in accordance with federal
262
Due Process and Equal Protection.
Defining sexually unsafe or risky behavior, as explained
above, is essential to forming the new rule in a way that best
protects the nation’s blood supply. Such language might say:
dishonors our system of limited government.”).
259. One source points out that, though African-Americans account for a
large portion of the HIV-positive population, there is no deferral for them and
that, were such a deferral to be put in place, it would obviously be seen as racist. Smith, supra note 60.
260. FDA Guidelines, supra note 7.
261. Donor Deferrals: The FDA’s Blood Policy on Gay Men Falls Short,
PITTSBURGH POST-GAZETTE (Jan. 4, 2015, 12:00 AM), http://www.post
-gazette.com/opinion/editorials/2015/01/04/Donor-deferrals-The-FDA-s-blood
-policy-on-gay-men-falls-short/stories/201501090002 (stating that under the
potential new policy, “many gay men still won’t be eligible to donate, and the
nation’s blood supply will continue to suffer for it”).
262. See U.S. CONST. amend. V; U.S. CONST. amend. XIV, § 1.
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“The FDA defines risky, unsafe, or dangerous sexual behavior
as having engaged in any of the following activities within thirty days of donation: (1) engaging in unprotected sex with one or
multiple partners; (2) engaging in protected or unprotected sex
with a sex worker; (3) engaging in protected or unprotected sex
in concurrence with intravenous or otherwise illegal drug use.
‘Unprotected’ sex is commonly understood to mean having sex
without the use of a condom and/or a diaphragm.” This language is a more accurate representation of what populations
present the most risk to the blood supply than does the current
FDA rule. Adding sixteen days to the fourteen day “safety”
window is designed to provide an extra level of reassurance
263
that the screened blood is truly safe.
The language contained within this proposed regulations
accomplishes what the FDA should have set out to do when it
first implemented the gay blood ban. It applies to individuals in
a manner that is not discriminatory because it does not identify
at-risk individuals by their sex, gender, sexual orientation, and
so on. Second, it provides a more than adequate level of protection for the blood supply by clearly defining sexually risky behavior that is likely to result in an infection with HIV, hepatitis
B, and other serious illnesses. With a blood donation guideline
containing this language, the FDA would finally have a rule
that is properly tailored to achieve its interests and the interests of the LGBT community.
CONCLUSION
The United States has a long and wearied history with the
264
HIV/AIDS epidemic. The fight against the epidemic still continues, with the rates of young MSM infections on the rise and
265
overall infection rates remaining stable. Nevertheless, the
FDA’s current policy on blood donation, though implemented at
266
a time when it was a logical solution, is no longer sensible. In
267
fact, the policy, in light of technological developments, changing social attitudes, and increasing legal rights for the LGBT
263. And to an individual wishing to donate blood, this is a much less burdensome requirement. For example, a gay man wishing to donate under the
current ban cannot if he has ever had sex. Under the proposed regulation, the
burden would mean waiting a year. But if, for instance, this ideal regulation
were implemented, a donor would have to wait a mere thirty days if he or she
engaged in risky behavior.
264. See A Timeline of AIDS, supra note 17.
265. HIV AND YOUNG MEN, supra note 73.
266. See supra Part II.B.
267. See Mohney, supra note 11.
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population is not only arbitrary, it may lead to ridiculous re269
sults.
A sensible solution for the modern world would apply to all
people regardless of sexual orientation, implement a reasonable
deferral period for those who have engaged in unsafe sex, and
take into account the current technology and attitudes of today.
A new policy is clearly needed so that those individuals like
270
Campbell, California Mayor Evan Low and other healthy gay
men who would otherwise be perfect donors were it not for the
capricious ban, may one day be allowed to participate in a system which saves lives on a daily basis.

268. See Sievers, supra note 3.
269. See, e.g., Darling, supra note 44.
270. Vongsarath, supra note 1.

